Published in Vopr Virusol on August 19, 2003
Design of four-helix bundle protein as a candidate for HIV vaccine. Protein Eng (1995) 0.97
Design of immunogens as components of a new generation of molecular vaccines. J Biotechnol (1996) 0.83
Construction of an artificial immunogen, a candidate DNA vaccine encoding multiple CTL epitopes of HIV-1. Dokl Biochem Biophys (2004) 0.83
[Vaccines, immunoglobulins, and test systems for the prevention and diagnosis of tick-borne encephalitis]. Vopr Virusol (2007) 0.82
[Constructing the reference panel of sera with standard level of IgG-antibodies]. Vopr Virusol (1997) 0.81
[ELISA and PCR test systems used to detect Crimean-Congo hemorrhagic fever virus]. Vopr Virusol (2007) 0.80
[Immunogenic and protective characteristics of recombinant Lassa virus NP protein]. Vopr Virusol (2002) 0.80
[A comparative study of the immunological indices in guinea pigs administered an inactivated Marburg virus]. Vopr Virusol (1992) 0.80
[The immunogenic properties of Marburg virus proteins]. Vopr Virusol (1992) 0.79
[Effects of tumor necrosis factor antiserum of the course of Marburg hemorrhagic fever]. Vestn Ross Akad Med Nauk (1998) 0.79
[Experimental study of possible treatment of Marburg hemorrhagic fever with desferal, ribavirin, and homologous interferon]. Vopr Virusol (1996) 0.79
Development of a candidate polyvalent live vaccine against human immunodeficiency, hepatitis B, and orthopox viruses. Dokl Biochem Biophys (2003) 0.78
[Study of certain indicators of immunity upon infecting CBA/Calac line mice with Lassa virus]. Vopr Virusol (1995) 0.78
[The immunity indices of animals immunized with the inactivated Marburg virus after infection with homologous virus]. Vopr Virusol (1994) 0.77
[Mechanisms of protective immune response in models of Marburg fever in monkeys]. Vopr Virusol (1995) 0.77
[Comparative study of hemostasis and cytokine production in experimental Dengue virus infection]. Vopr Virusol (2007) 0.76
[An experimental study of possibility of treatment of hemorrhagic fever Marburg by Remicade]. Vestn Ross Akad Med Nauk (2004) 0.76
[A cultured concentrated inactivated vaccine against tick-borne encephalitis studied during the immunization of children and adolescents]. Zh Mikrobiol Epidemiol Immunobiol (2000) 0.76
[Immune response in oral and rectal immunization by the attenuated strain of salmonella carrying the HIV DNA-vaccine]. Vopr Virusol (2003) 0.75
[Induction of immune mediators in human cultured mononuclear cells by Marburg virus]. Vopr Virusol (1998) 0.75
[The immunity indices in the infection of mice of different strains with the Machupo virus]. Vopr Virusol (1993) 0.75
[Immunologic indicators in vaccinated mice with Machupo virus infection]. Vopr Virusol (1997) 0.75
Primary characterization of SARS coronavirus strain Frankfurt 1. Dokl Biol Sci (2004) 0.75
[Different systems of delivery of HIV-1 DNA vaccine encoding the multiepitope CTL-immunogene]. Vestn Ross Akad Med Nauk (2005) 0.75
[Analysis of the stability of some properties of tick-borne encephalitis virus (strain 205) upon passaging in mice]. Vopr Virusol (1996) 0.75
[Interferon-stimulating properties of immunomodulators]. Vopr Virusol (1990) 0.75
[Detection and antigenic characteristics of the recombinant nucleocapsid proteins of Lassa and Marburg viruses]. Vopr Virusol (2012) 0.75
[Design of reference panels of serum for testing the quality of HIV antibody tests in practical laboratories]. Vopr Virusol (1998) 0.75
[A standard panel of human immunodeficiency virus-positive and -negative blood sera for assessing the sensitivity and specificity of diagnostic immunoenzyme test systems]. Vopr Virusol (1990) 0.75
A model of molecular constructions of a combined bivaccine. Dokl Biochem Biophys (2002) 0.75
[Virological and immunological indices in patients with multiple sclerosis]. Vestn Ross Akad Med Nauk (2004) 0.75
[Anti-measles DNA-immunization in experiment: immunogenicity and safety]. Vopr Virusol (2005) 0.75
[Sensitivity and specificity of the PCR-test-system for diagnosing HIV infections]. Vopr Virusol (1998) 0.75
[Preparations for serodiagnosis of diseases due to causative agents of ixode tick-borne Borreliosis (Lyme disease). Communication 2. Comparative study of recombinant enzyme immunoassay test-systems (rELISA) for serological diagnosis of ixode tick-borne Borreliosis]. Antibiot Khimioter (2004) 0.75
[Experimental study of the possibility of emergency prophylaxis of Bolivian hemorrhagic fever]. Vopr Virusol (1996) 0.75
[Pneumonia caused by Chlamydophila (Chlamydia) pneumoniae: clinical data, diagnosis, and therapy]. Antibiot Khimioter (2001) 0.75
[Immunological status of patients with epidemic parotitis]. Vopr Virusol (2001) 0.75
[Production of immune mediators, induced by Lassa virus, in a human mononuclear cell culture]. Vopr Virusol (2001) 0.75
[The quality standardization of a national vaccine against yellow fever]. Zh Mikrobiol Epidemiol Immunobiol (1990) 0.75
[Experimental study of the effect of the drug desferal and serum against tumor necrosis factor on the course of the infectious process in arenaviral hemorrhagic fever]. Antibiot Khimioter (1996) 0.75
[Isolation and study of the immunobiological properties of the recombinant proteins of measles virus]. Mol Gen Mikrobiol Virusol (2008) 0.75
[Combined experimental use of vaccine against acute human encephalomyelitis and immunomodulators]. Antibiot Khimioter (1992) 0.75
[Immunization of rabbits with Lassa virus]. Vopr Virusol (1990) 0.75
[Immunoenzyme analysis in screening for antibodies against herpes simplex virus]. Vopr Virusol (1990) 0.75
[Comparative evaluation of Leningrad-3 mumps vaccine virus neurovirulence in a neonatal rat model]. Vopr Virusol (2011) 0.75
[Preparations for serodiagnosis of diseases due to causative agents of ixode tick-borne borreliosis (Lyme disease). Communication 1. Comparative study of the 1st generation enzyme immunoassay test-systems for detection of antibodies to Borrelia burkdorferi sensu lato]. Antibiot Khimioter (2004) 0.75
[Collection of pathogenic viruses: state of the problem and prospects]. Vopr Virusol (1997) 0.75
[Development and application of an immunoenzyme test system for diagnosing Ebola fever]. Vopr Virusol (1995) 0.75
[Characteristics of the immune response in mice immunized with the inactivated Lassa virus]. Vopr Virusol (1989) 0.75
[Isolation and study of recombinant strains of Salmonella typhimurium SL 7207, producing HBcAG and HBcAG-HBs]. Vopr Virusol (2000) 0.75
[Virus strain specific serum neutralizing antibodies in children and adolescents immunized with a Russian mumps vaccine]. Vopr Virusol (2011) 0.75
[A method of taking finger blood samples for mass examinations for the presence of antibodies to the human immunodeficiency virus]. Zh Mikrobiol Epidemiol Immunobiol (1990) 0.75
[An evaluation of immunoenzyme test systems for detecting HIV antibodies in an international trial]. Vopr Virusol (1990) 0.75
[A recombinant vaccinia virus expressing the middle preS2-S envelope protein of the hepatitis B virus. The induction of humoral and cellular immunity by the immunization of laboratory animals]. Dokl Akad Nauk SSSR (1990) 0.75
[Serodiagnosis of chlamydiosis: "Chlamy-IgG-DS-Tr"-- the first domestic immunoenzyme recombinant test-system for determination of anti-Chlamydia trachomatis class G antibodies]. Antibiot Khimioter (2000) 0.75
[Comparative study of the effectiveness of HBcAg presentation to the immune system using attenuated Salmonella strains, serovars S.enteritidis and S.typhimurium]. Zh Mikrobiol Epidemiol Immunobiol (2002) 0.75
[In vitro study of antiviral activity of Myramistin against measles and mumps viruses]. Antibiot Khimioter (2005) 0.75
[Preparation of rabbit antiserum to Ebola virus]. Vopr Virusol (1995) 0.75
[The capacities of current test systems to verify early HIV infection]. Vopr Virusol (2009) 0.75
[Artificial anti-HIV immunogens and methods of their delivery]. Vestn Ross Akad Med Nauk (2003) 0.75
[Construction and study of antigenic characteristics of recombinant salmonella strain producing TBI protein]. Vopr Virusol (2002) 0.75
[The study of protective properties of attenuated strain of Argentinian hemorrhagic fever]. Vopr Virusol (1997) 0.75
[Features of formation of antiviral resistance upon local application of the interferon inducer ridostin]. Vopr Virusol (1997) 0.75
[The evaluation of a commercial EIA test system for determining the specific activity of antiherpetic preparations]. Vopr Virusol (1991) 0.75
[The principles for standardizing serum panels intended for the quality assessment of diagnostic test systems (exemplified by an immunoenzyme test system for detecting HIV antibodies)]. Vopr Virusol (1992) 0.75
[Isolation of purified Ebola virus]. Vopr Virusol (1995) 0.75
[Immunogenicity and stability of a Soviet inactivated cultured vaccine against Japanese encephalitis]. Vopr Virusol (1991) 0.75
[The sensitivity of different cell culture lines to the Marburg virus]. Vopr Virusol (1992) 0.75
[The comparative characteristics of the peroxidase conjugates used in Soviet immunoenzyme test systems for detecting HIV antibodies]. Vopr Virusol (1993) 0.75
[Adaptation of different modifications of enzyme immunoassay and immune blot assay to assess the candidate vaccine HIVREPOL against HIV/AIDS]. Vopr Virusol (2006) 0.75
[Comparative study in an experiment on the efficacy of 2 regimens of vaccinal immunization against human acute encephalomyelitis]. Vopr Virusol (1988) 0.75
[The principles of creating standard serum panels with a low concentration of HIV-1 antibodies for the quality control of commercial immunoenzyme test systems]. Vopr Virusol (1994) 0.75
[Characteristics of parotitis virus, isolated in Siberia]. Vopr Virusol (1998) 0.75
[Vitaherpavac is the first Russian herpes simplex virus vaccine obtained on the Vero B continuous cell line]. Vopr Virusol (2009) 0.75
[Effect of immunostimulants on the intensity of vaccinal antirabies immunity]. Vopr Virusol (1985) 0.75
Cloning, expression, and purification of the nucleocapsid protein of SARS coronavirus. Dokl Biochem Biophys (2004) 0.75
[Antiviral activity of yeast dsRNA in experimental infection caused by the human acute encephalomyelitis virus]. Vopr Virusol (1988) 0.75
[Functional state of specific immunity in children and teenagers vaccinated against mumps]. Vopr Virusol (2010) 0.75
[The relationship of the antigenic characteristics of the tick-borne encephalitis virus to the level of the protective activity of inactivated cultured vaccines]. Zh Mikrobiol Epidemiol Immunobiol (1992) 0.75
[Preparations for serodiagnosis of diseases due to causative agents of ixodes tick-borne borreliosis (Lyme disease). Communication 3. Comparative study of enzyme immunoassay test-systems for detection of IgM to Borrelia burgdorferi sensu lato]. Antibiot Khimioter (2004) 0.75
[Cytokine production during experimental infection of mice with tick-borne encephalitis virus]. Vopr Virusol (2003) 0.75
[Comparative study of inactivated cultured vaccines against tick-borne encephalitis manufactured in Russia and in Austria by the "Immuno" firm]. Vopr Virusol (1996) 0.75
[The isolation of concentrated preparations of the Machupo virus]. Vopr Virusol (1992) 0.75
[The immunological indices of guinea pigs modelling Marburg hemorrhagic fever]. Vopr Virusol (1995) 0.75
[Comparative evaluation of two enzyme immunoassays for detection of immunoglobulin G antibodies to mumps virus]. Vopr Virusol (2012) 0.75
[Immune response in vaccinated and non-vaccinated mice infected with tick-borne encephalitis virus]. Vopr Virusol (2006) 0.75
[The immunity indices of BALB/c mice immunized with an inactivated antigen of the Machupo virus]. Vopr Virusol (1994) 0.75
[Development of sera reference panels for quality control of ELISA diagnostic kits in Russia]. Vestn Ross Akad Med Nauk (1998) 0.75
[Study of the immunobiological properties of parotitis viral strains]. Vopr Virusol (1995) 0.75
[Evaluation of the first domestic immunoenzyme recombinant test-system "Khlami-IGA-DS-Tr" for detection of class A antibodies to Chlamydia trachomatis]. Klin Lab Diagn (2002) 0.75
[Comparative study of cellular and humoral immunity as well as of resistance to the rabies virus in rabies vaccination]. Vopr Virusol (1985) 0.75
[Specific humoral immunity after single immunization with mumps vaccine: data of a 3-year follow-up]. Vopr Virusol (2011) 0.75